BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
13 août 2024 16h30 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024
07 août 2024 07h00 HE
|
BioCardia, Inc.
BioCardia will provide a Q2 2024 corporate update and report its financial results by conference call on Tuesday August 13, 2024
BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family
30 juil. 2024 07h00 HE
|
BioCardia, Inc.
BioCardia, Inc., today reported it has submitted a 510(k) for approval of its patented Morph® DNA™ Steerable Introducer Sheath with the FDA.
Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure
25 juil. 2024 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
17 juil. 2024 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction
08 juil. 2024 07h00 HE
|
BioCardia, Inc.
CellProthera, and BioCardia [Nasdaq: BCDA], today announce success from a collaborative Phase II trial of ProtheraCytes for the treatment of AMI.
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
07 juin 2024 07h00 HE
|
BioCardia, Inc.
BioCardia announces that the USPTO has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a 2036 expiration date.
BioCardia Announces Reverse Stock Split
21 mai 2024 17h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
14 mai 2024 16h02 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
09 mai 2024 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...